Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVICEL as an adjunct to sutured dural repair in elective cranial surgery
NL-OMON36810Phase 3Active, not recruiting
- Sponsor
- OMRIX Biopharmaceuticals, Inc.
- Start
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of porcine fibrin sealant in cerebrospinal fluid leak (2 arms), sponsored by OMRIX Biopharmaceuticals, Inc. Primary endpoints: Primary efficacy endpoint, CSF leakage within 5 days and 3 more. Started Nov 2010; status: active, not recruiting.
02
Drugs
porcine fibrin sealant
03
Conditions
cerebrospinal fluid leak
Beyond the preview
Go deeper on NL-OMON36810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36810.